Trials / Unknown
UnknownNCT03864575
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
NICE-COMBO: An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the investigated dose of celecoxib during the safety run-in phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib 400 mg | Celecoxib 400 mg/day in combination with nivolumab fixed dose |
Timeline
- Start date
- 2019-08-15
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
- First posted
- 2019-03-06
- Last updated
- 2019-07-12
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03864575. Inclusion in this directory is not an endorsement.